The role of serum osteopontin (OPN) as a prognostic and predictive marker in patients with advanced gastric cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e14627-e14627 ◽  
Author(s):  
O. Yazici ◽  
H. Akbulut ◽  
N. Akgun ◽  
G. Utkan ◽  
B. Yalcin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Predictive Marker

Role of nk activating receptor (NKP30) in immunosuppression of advanced gastric cancer patients

2001 ◽  
Vol 37 ◽  
pp. S229
Author(s):  
J.C. Lee ◽  
S.R. Park ◽  
S.H. Lee ◽  
M.W. Sung ◽  
D.S. Heo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Gastric Cancer Patients ◽  
Activating Receptor

scholarly journals New approaches to prediction and treatment of advanced gastric cancer based on molecular-biological parameters

2017 ◽  
Vol 94 (11) ◽  
pp. 812-820
Author(s):  
Evgeniya S. Fedoseeva ◽  
M. V. Savostikova ◽  
M. N. Narimanov ◽  
A. A. Pashaev ◽  
S. S. Kirichenko ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Predictive Value ◽  
Biological Parameters ◽  
Hereditary Predisposition ◽  
New Approaches ◽  
Brca 1 ◽  
Neoplastic Process

This review is designed to discuss possibilities for the treatment of advanced gastric cancer with reference to the prognostic and predictive value of molecular-biological parameters and the influence of hereditary predisposition to the development of neoplastic process. The data on modern pharmacotherapy of this disease based on the knowledge of molecular-biological parameters are presented including the following markers: HER2/neu, VGFR, c-met, TUBB3, CDH-1, BRCA-1, EGFR, TGF-ß, p53, Ki67 and PCNA. It is emphasized that the role of molecular-biological parameters associated with advanced gastric cancer is ambiguous. The prognostic and predictive significance of some of the markers is confirmed while that of others remains to be elucidated and requires further research.

scholarly journals Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

2013 ◽  
Vol 24 (10) ◽  
pp. 2581-2588 ◽  
Author(s):  
L. Stenholm ◽  
J. Stoehlmacher-Williams ◽  
S.E. Al-Batran ◽  
N. Heussen ◽  
S. Akin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Prognostic Role ◽  
Translational Study

What Is the Role of Mitomycin C in Advanced Gastric Cancer?

2005 ◽  
Vol 28 (3) ◽  
pp. 125-126 ◽  
Author(s):  
Geoff Chong ◽  
David Cunningham
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Mitomycin C

Role of bursectomy for advanced gastric cancer: Result of a case–control study from a large volume hospital

2013 ◽  
Vol 39 (12) ◽  
pp. 1407-1414 ◽  
Author(s):  
B.W. Eom ◽  
J. Joo ◽  
Y.W. Kim ◽  
J.M. Bae ◽  
K.B. Park ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Large Volume ◽  
Case Control Study ◽  
Case Control ◽  
Control Study

The vascular endothelial growth factor as a predictive and prognostic factor in patients with advanced gastric cancer treated with docetaxel, cisplatin, and 5-florouracil (DCF) regimen.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15191-e15191
Author(s):  
Sedef H. Aktas ◽  
Hakan Akbulut ◽  
Ozan Yazici ◽  
Nurullah Zengin ◽  
Nalan Akgun ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Predictive Marker ◽  
Vascular Endothelial ◽  
Gastric Cancer Patients ◽  
Endothelial Growth Factor

e15191 Background: Vascular endothelial growth factor (VEGF) is a key element stimulating the angiogenesis in solid tumors. In the current study, we aimed to assess the role of plasma VEGF levels as a prognostic and predictive marker for advanced gastric cancer patients treated with a modified docetaxel, cisplatinum and 5-florouracil (DCF) regimen. Methods: Thirty consecutive patients treated with a modified DCF regimen were included in the study. The plasma VEGF levels of the patients before treatment and following two cycles of chemotherapy were assayed. Results: The modified DCF regimen was well tolerated and yielded a median overall survival (OS) time of 9,0 months and 2-year OS rate of 20%. Good performance status, lower pre-treatment VEGF levels,and decrease in VEGF levels following chemotherapy were found to be independent prognostic factors for OS. Conclusions: The results of the current study suggest that the corrected plasma levels of VEGF could be used as a prognostic factor for advanced gastric cancer patients and a decrease in VEGF levels following 2 cycles of chemotherapy as a predictive marker for patients receiving DCF chemotherapy regimen.

Sign in / Sign up

Export Citation Format

Share Document